Opsidio
PA - Bryn MawrBiotechnology
Focus: Opsidio is a publicly-listed monoclonal antibody biotech founded in 2019, focused on oncology with a diversified pipeline including dermatology programs. The company operates at modest scale with early-stage clinical programs.
Profile data last refreshed 2d ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Opsidio
AI assessmentNot HiringNo open roles listed right now. Follow Opsidio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
OpSCF
Atopic DermatitisClinical Trials (1)
NCT06101823Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe Atopic Dermatitis
Phase 2Help build intelligence for Opsidio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.